Bloodstream Infection Due to Piperacillin/Tazobactam Non-Susceptible, Cephalosporin Susceptible Escherichia Coli: A Missed Opportunity for DE-Escalation of Therapy by Carlisle, Leah et al.
University of South Carolina 
Scholar Commons 
Faculty Publications Pharmacy, College of 
12-1-2018 
Bloodstream Infection Due to Piperacillin/Tazobactam Non-
Susceptible, Cephalosporin Susceptible Escherichia Coli: A 
Missed Opportunity for DE-Escalation of Therapy 
Leah Carlisle 
Julie Ann Justo 
justoj@cop.sc.edu 
Majdi N. Al-Hasan 
majdi.alhasan@uscmed.sc.edu 
Follow this and additional works at: https://scholarcommons.sc.edu/phar_facpub 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Publication Info 
Published in Antibiotics, Volume 7, Issue 4, 2018. 
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license 
(http://creativecommons.org/licenses/by/4.0/). 
This Article is brought to you by the Pharmacy, College of at Scholar Commons. It has been accepted for inclusion 
in Faculty Publications by an authorized administrator of Scholar Commons. For more information, please contact 
dillarda@mailbox.sc.edu. 
antibiotics
Case Report
Bloodstream Infection due to Piperacillin/Tazobactam
Non-Susceptible, Cephalosporin-Susceptible
Escherichia coli: A Missed Opportunity for
De-Escalation of Therapy
Leah Carlisle 1, Julie Ann Justo 2,3 and Majdi N. Al-Hasan 4,5,*
1 College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA; leahc@email.sc.edu
2 Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy,
University of South Carolina, Columbia, SC 29208, USA; justoj@cop.sc.edu
3 Department of Pharmacy, Palmetto Health Richland, Columbia, SC 29203, USA
4 School of Medicine, University of South Carolina, Columbia, SC 29209, USA
5 Department of Medicine, Division of Infectious Diseases, Palmetto Health University of South Carolina
Medical Group, Columbia, SC 29203, USA
* Correspondence: majdi.alhasan@uscmed.sc.edu; Tel.: +1-803-540-1062; Fax: +1-803-540-1079
Received: 31 October 2018; Accepted: 29 November 2018; Published: 1 December 2018


Abstract: An increasing number of reports describing Escherichia coli isolates with piperacillin/tazobactam
resistance, despite retained cephalosporin susceptibility, suggest further emergence of this phenotypic
resistance pattern. In this report, a patient with metastatic breast cancer presented to medical
care after two days of chills, nausea, vomiting, reduced oral intake, and generalized weakness.
Blood and urine cultures grew E. coli as identified by rapid diagnostics multiplex PCR and
MALDI-TOF, respectively. The patient continued to manifest signs of sepsis with hypotension and
tachypnea during the first three days of hospitalization despite empirical antimicrobial therapy with
intravenous piperacillin/tazobactam. After in vitro antimicrobial susceptibility testing demonstrated
a piperacillin/tazobactam minimal inhibitory concentration (MIC) of 64 and a ceftriaxone MIC
of ≤1 mcg/mL, antimicrobial therapy was switched from intravenous piperacillin/tazobactam to
ceftriaxone. All symptoms and signs of infection resolved within 48 h of starting ceftriaxone therapy.
This report describes the clinical failure of piperacillin/tazobactam in the treatment of a bloodstream
infection due to E. coli harboring a phenotypic resistance pattern of isolated piperacillin/tazobactam
non-susceptibility. The case demonstrates the role of cephalosporins as potential treatment options
and highlights the value of early de-escalation of antimicrobial therapy based on rapid diagnostic
testing for microbial identification.
Keywords: Bacteremia; sepsis; pyelonephritis; antibiotics; antimicrobial stewardship; beta-lactam/
beta-lactamase inhibitors; ESBL; TEM-1
1. Case
A woman over 70 years old presented to a local emergency room in the summer of 2017 with a
2-day history of chills, nausea, vomiting, reduced oral intake, and generalized weakness. She was
unable to get out of bed over the past 24 h. Upon review of systems, she had no urinary symptoms,
abdominal pain, diarrhea, or other complaints. Past medical history was remarkable for metastatic
breast cancer, hypertension, and depression. Her home medications included oral letrozole, sertraline,
amlodipine, and carvedilol. The patient was briefly hospitalized three months prior for new brain
metastases. However, she did not receive antimicrobials or chemotherapy during that hospitalization
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or elsewhere over the past 6 months. She had no other known healthcare exposures or invasive
procedures over the same period. The patient had no documentation of prior infections or colonization
with multidrug-resistant bacteria.
The patient had signs of sepsis on initial presentation with hypotension (blood pressure:
61/39 mmHg) and tachypnea (respiratory rate: 27 breaths/minute). Her tympanic temperature
was 99.2 degrees Fahrenheit, and her heart rate was 76 beats per minute. She was alert and awake
during the physical examination with dry skin and mucus membranes. A tunneled central venous port
in the anterior chest had no erythema, drainage, or tenderness to touch. Significant laboratory findings
included a peripheral white blood cell (WBC) count of 12,400/mm3 with bandemia (21%), elevated
serum creatinine from baseline (2.9 mg/dL), and high serum procalcitonin (187 ng/mL). Urinalysis
with microscopy demonstrated large leukocyte esterase, 95 WBCs with few WBC clumps, and 6 red
blood cells. Rare bacteria were observed by urine microscopic examination. No new pulmonary
infiltrates were noted on a chest X-ray.
The patient was admitted to the intensive care unit for management of suspected sepsis.
Intravenous fluid resuscitation and empirical broad-spectrum antimicrobials (intravenous vancomycin
and piperacillin/tazobactam) were started following collection of blood and urine cultures.
An antimicrobial stewardship alert was triggered by the growth of Gram-negative bacilli on blood
cultures after 12 h of collection. A BioFire FilmArray® multiplex PCR Blood Culture Identification
(BCID) panel detected Enterobacteriaceae and Escherichia coli. The Klebsiella pneumoniae carbapenemase
(KPC) gene was not detected. A urine culture also grew Escherichia coli as identified by MALDI-TOF.
At this point, the local antimicrobial stewardship team recommended discontinuation of vancomycin.
Recommendations also included de-escalation of antimicrobial therapy from piperacillin/tazobactam
to ceftriaxone given growth of E. coli in the bloodstream and the patient’s low risk of extended-spectrum
beta-lactamases (ESBLs) given the absence of recent antimicrobial use or prior infections or colonization
with ESBL-producing bacteria [1,2]. The primary team discontinued vancomycin; however, they
preferred to continue intravenous piperacillin/tazobactam at 2.25 g every 6 h (dose adjusted
for calculated creatinine clearance of 15 mL/min) until the availability of in vitro antimicrobial
susceptibility testing results of the E. coli isolate.
Following an initial relative improvement in hemodynamics with fluid resuscitation, the patient’s
clinical response plateaued during the first three days of antimicrobial therapy. She continued
to manifest signs of sepsis with a systolic blood pressure of <100 mmHg and a respiratory rate
of >22 breaths/minute. On the fourth day of hospitalization, she developed a fever (102 degrees
Fahrenheit) and new-onset diarrhea (5 watery bowel movements within 24 h), and her respiratory rate
increased from 24–26 to 30 breaths/minute. Clostridioides difficile PCR was positive in a stool sample.
Retroperitoneal ultrasound did not demonstrate ureteric obstruction or hydro-nephrosis. The in vitro
antimicrobial susceptibility results of the E. coli bloodstream and urinary isolate are demonstrated
in Table 1. Non-susceptibility to piperacillin/tazobactam via the automated VITEK® 2 system was
confirmed using the Kirby–Bauer method. In addition, ESBL screening by disk diffusion using
cefotaxime/clavulanate combination disks was negative. The primary team requested a consultation
with a specialist in Infectious Diseases for antimicrobial management.
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Table 1. In vitro antimicrobial susceptibility results of E. coli isolate.
Antimicrobial Agent MIC Categorical Interpretation
Ampicillin ≥32 Resistant
Amoxicillin/clavulanate 16 Intermediate
Piperacillin/tazobactam 64 Intermediate
Cefazolin 8 Variable interpretation *
Cefoxitin ≤4 Susceptible
Ceftriaxone ≤1 Susceptible
Cefepime ≤1 Susceptible
Ertapenem ≤0.5 Susceptible
Meropenem ≤0.25 Susceptible
Ciprofloxacin ≤0.25 Susceptible
Gentamicin ≤1 Susceptible
Trimethoprim/sulfamethoxazole ≥320 Resistant
MIC: Minimal inhibitory concentration in mcg/mL. * Despite similar cefazolin MICs, interpretation was resistant
for the bloodstream isolate but susceptible for the urinary isolate due to different susceptibility breakpoints per the
2017 guidelines from the Clinical and Laboratory Standards Institute.
2. Treatment Strategy and Patient Outcome
The Infectious Diseases consultation team initiated oral vancomycin for the treatment of the
C. difficile infection. Piperacillin/tazobactam was discontinued and intravenous ceftriaxone at 2 g every
24 h was started for the treatment of the E. coli bloodstream infection secondary to a urinary source.
The patient showed significant clinical improvement within 48 h of the new antimicrobial regimen.
The fever, tachypnea, and hypotension all resolved. Antihypertensive medications were restarted due
to consistent systolic blood pressure readings greater than 130 mmHg. The patient was discharged
from the hospital after successful treatment of both infections with no evidence of recurrence in the
subsequent 12 months.
3. Discussion
E. coli is the most common bacterial cause of bloodstream infections (BSI) in North America and
Europe [3]. A higher incidence rate in women than in men is due to predominance of the urinary tract
as the source of E. coli BSI [4]. Appropriate empirical antimicrobial therapy is associated with improved
survival in critically ill patients with BSI and a shorter hospital length of stay overall [5,6]. Increasing
rates of antimicrobial resistance among E. coli bloodstream isolates have complicated empirical
antimicrobial management [4,7]. Utilization of broad-spectrum antimicrobial agents, particularly
piperacillin–tazobactam, has increased over the past two decades in United States hospitals [8].
The empirical use of piperacillin/tazobactam in patients with suspected Gram-negative BSI provides
antimicrobial coverage for Pseudomonas aeruginosa and possibly ESBL-producing Enterobacteriaceae [9].
However, this “one-size-fits-all approach” may not be necessary beyond the first 24–48 h of presentation
in the era of rapid diagnostics and prediction of antimicrobial resistance [1,2]. A recent study
demonstrated that de-escalation of antimicrobial therapy to ceftriaxone is safe and effective once
the bloodstream isolate has been identified as E. coli, in the absence of risk factors for ESBLs [1].
In the absence of molecular or PCR testing to determine the exact resistance mechanism,
interpretation of the phenotypic resistance pattern is crucial to optimizing antimicrobial therapy.
The E. coli isolate in this case is resistant to ampicillin, suggesting the presence of TEM-1
beta-lactamase. Non-susceptibility to both beta-lactam/beta-lactamase inhibitor combinations—
amoxicillin/clavulanate and piperacillin/tazobatam—suggests either TEM-1 hyperproduction or
an inhibitor resistance mechanism [10]. This is supported by the low minimal inhibitory concentrations
(MICs) of the high-generation cephalosporins cefoxitin and ceftriaxone, which argue against the
possibilities of AmpC beta-lactamases and ESBLs, respectively [11]. In addition, a negative ESBL
screening test confirms the lack of ESBL production in this isolate.
Antibiotics 2018, 7, 104 4 of 5
This case demonstrates many benefits of early de-escalation of antimicrobial therapy in patients
with E. coli BSI. First, in the era of increasing antimicrobial use and resistance, there are no guarantees
that the broader-spectrum agent, piperacillin/tazobactam, includes antimicrobial coverage for more
E. coli isolates than a narrower-spectrum agent, ceftriaxone. There are increasing numbers of reports
describing the emergence of piperacillin/tazobactam resistance among E. coli isolates despite retained
susceptibility to cephalosporins in over 20 states [12]. Tandem amplification of a complete transposon
containing the bla-TEM-1 gene under selective antimicrobial pressure has been described as a potential
explanation of this resistance pattern [13]. A recent study demonstrates relatively fair agreement
between various automated in vitro antimicrobial susceptibility testing methods in identifying
this phenotypic resistance [14]. It is speculated that increasing use of piperacillin/tazobactam in
hospitals may have contributed to the emergence of isolated piperacillin/tazobactam resistance
among E. coli isolates. This phenotypic resistance pattern does not appear to be uncommon. At our
healthcare system of four community hospitals in central South Carolina, 3.1% (86/2733) of all-source
E. coli isolates in the 2016 and 2017 calendar years were non-susceptible to piperacillin/tazobactam,
despite retained susceptibility to ceftriaxone. Whereas piperacillin/tazobactam may add in vitro
activity against E. coli isolates that harbor CTX-M-15 or other ESBLs, it may miss as many isolates
with isolated piperacillin/tazobactam resistance, particularly in settings with a relatively low
prevalence of ESBLs [2,9]. Second, early de-escalation of antipseudomonal beta-lactams, including
piperacillin/tazobactam, in patients with Enterobacteriacieae BSI has been associated with a threefold
reduction in the risk of C. difficile infection in a recent investigation [15].
Reports on optimal antimicrobial therapy for BSI due to E. coli with isolated
piperacillin/tazobactam resistance remain scarce. A prior study, an animal model for treatment of
such E. coli isolates, suggested that piperacillin/tazobactam may still be effective in vivo despite
in vitro non-susceptibility to this agent. To our knowledge, the current report is the first to describe
the clinical failure of piperacillin/tazobactam in the treatment of BSI due to piperacillin/tazobactam
non-susceptible, cephalosporin-susceptible E. coli. The main limitation of this report is the lack
of additional testing to determine the E. coli group or serotype, or to confirm the exact resistance
mechanism. Further clinical studies on risk factors and optimal antimicrobial treatment options
for infections due to E. coli isolates with this emerging phenotypic resistance pattern of isolated
piperacillin/tazobactam resistance are warranted.
4. Conclusions
E. coli resistance to piperacillin/tazobactam with retained susceptibility to cephalosporins
is an emerging phenotypic resistance pattern. This case study describes clinical failure of
piperacillin/tazobactam in the treatment of BSI and sepsis due to an E. coli with isolated
piperacillin/tazobactam resistance. Rapid clinical response after switching therapy to ceftriaxone
supports the use of in vitro antimicrobial susceptibility testing results in the selection of antimicrobials
for treatment of BSI due to these E. coli isolates. The emergence of this phenotypic resistance pattern
discourages the non-stratified utilization of broad-spectrum agents such as piperacillin/tazobactam for
the empirical therapy of E. coli BSI. The report supports early de-escalation of antimicrobial therapy to
ceftriaxone based on identification of E. coli in the bloodstream using rapid diagnostics in the absence
of risk factors for ESBLs. Early de-escalation of antipseudomonal beta-lactams may also reduce the
risk of C. difficile infection in patients with Enterobacteriacieae BSI.
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